PDCD1 and non-small cell lung carcinoma: Nevertheless, the results of this study suggest that 18F-FDG PET/CT, which is a relatively non-invasive procedure, might be a useful tool to predict the efficacy of anti-PD-1 mAbs in patients with advanced or recurrent NSCLC.